|
Faculty
 |
 |
 |
Jeanne Palmer, MD
Associate Professor
Section Head of Hematology
Director, Blood and Marrow
Transplant Program
Mayo Clinic
Phoenix, Arizona
|
Raajit Rampal, MD
Associate Member
Clinical Director of the
Leukemia Service
Memorial Sloan Kettering
Cancer Center
New York, New York
| Pankit Vachhani, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Alabama
at Birmingham
Birmingham, Alabama |
Program Overview
Despite the significant advances in understanding MF pathophysiology and outcomes attributed to JAK inhibitors, challenges remain in the development of treatment plans tailored for the individual patient. Join the discussion on the development and optimization of individualized treatment strategies for MF patients in the real-world clinical practice setting.
This discussion includes a Q&A session, take this opportunity to get questions answered.
Agenda
| 10 minutes |
Individualizing Therapy in MF: The Path from Accurate Diagnosis and Assessment to Optimized Treatment Plans |
| 40 minutes |
Putting the Clinician Toolbox for MF into Clinical Practice: Developing Targeted, Individualized Treatment Plans for Optimized Patient Outcomes |
| 10 minutes |
Conclusion, Audience Question & Answer Session |
Target Audience
This educational activity is designed for community-based hematologists, hematologist/oncologists and community-based advanced practice providers in hematology/oncology who provide care to patients with myelofibrosis.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Outline strategies for effectively and accurately diagnosing MF and for stratifying MF patients according to risk
- Correlate safety and efficacy data for new and emerging therapies in MF with patient types and clinical scenarios most appropriate for each
- Identify TEAEs associated with therapeutic options for MF and outline proactive clinical strategies for minimizing and/or mitigating these TEAEs if and when they develop
- Identify strategies for developing optimized, tailored treatment plans for individual patients with MF
Accreditation/CE
 |
CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
 |
CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-23-011-L01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
|
|
Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-011-167
|
|
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Planning Committee
Joan Meyer, RN, MHA, Executive Director, and Cassie Rametta, Senior Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
|
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity.
CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation
If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x114 or [email protected] |
|
|
| Provided by |
 |
Supported by educational grants from Constellation Pharmaceuticals Inc., A MorphoSys Company,
CTI BioPharma Corp., Incyte Corporation, and Karyopharm Therapeutics Inc. |
|
|
|
|
